CAS: 181219-01-2; 4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)Pyridine

相似化合物

1692-15-5 913835-65-1 660867-80-1

上下游产品

CAS号76-09-5 频哪醇 | CAS号1692-15-5 4-吡啶硼酸 | CAS号110-86-1 吡啶 | CAS号73183-34-3 双戊酰二硼 | CAS号15854-87-2 4-碘吡啶 | CAS号126-30-7 新戊二醇(NPG) | CAS号1120-87-2 4-溴吡啶 | CAS号106047-33-0 5-Bromo-2,4'-bi... | CAS号39795-60-3 4-(4-溴苯基)吡啶 | CAS号194861-72-8 9,10-二(4-吡啶基)蒽 | CAS号20308-98-9 4-anthracen-9-y... | CAS号108-89-4 4-甲基吡啶 | CAS号581-47-5 2,4'-联吡啶 | CAS号319430-87-0 4,4'-双(4-吡啶基)联苯 | CAS号113682-56-7 1,4-二(对吡啶基)苯 | CAS号647835-35-6 2,6-diphenyl-4-... | CAS号647835-42-5 2,6-bis(4-chlor...

4-氨基吡啶置于sodium Nitrate,Tetrafluoroboric Acid,正丁基锂体系中,用 乙醚,正己烷,水 用作溶剂,化学反应 3.5H,反应生成4-吡啶硼酸频哪醇酯
参考文献:A Heterofunctional Ligand Approach For The Preparation Of High Connectivity Coordination Polymers: Combining A "bridge" And "pillar" In One Ligand
标题:A Heterofunctional Ligand Approach For The Preparation Of High Connectivity Coordination Polymers: Combining A "bridge" And "pillar" In One Ligand
摘要:提出了一种将网状合成和柱塞设计元素结合的新策略.
Doi:10.1039/d0Ce01020K

专利信息

专利号:US-11512097-B2
优先权日:2019-11-25
标题 :Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use
发明人：ALLEN JENNIFER R; BELTRANI MICHELA; BOURBEAU MATTHEW P; DAMYANOVA TEODORA P; LINGARD IAIN; MINATTI ANA E; VINCETTI PAOLO
权利人:AMGEN INC
摘要:The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5Dâ€?). The compounds have a general Formula I n nwherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:CA-2693182-A1
优先权日:2007-06-29
标 题:Pyrimidine compounds, methods of synthesis thereof, and use thereof in the treatment of raf kinase-mediated disorders

专利号:US-2007275968-A1
优先权日:2004-09-07
标 题 :Substituted Biphenyl Derivative
发明人：KURATA HITOSHI; NISHIMATA TOYOKI; WATANABE YUKIKO; EBISAWA MASAYUKI; FUJIMOTO TEPPEI; KOBAYASHI HIDEKI
权利人:KURATA HITOSHI; NISHIMATA TOYOKI; WATANABE YUKIKO; EBISAWA MASAYUKI; FUJIMOTO TEPPEI; KOBAYASHI HIDEKI
摘要:The present invention relates to a biaryl derivative or a pharmacologically acceptable salt thereof having an excellent collagen-synthesis inhibition activity. A biaryl derivative having a structure represented by the following General Formula (I) or a pharmacologically acceptable salt thereof: n nwherein n R 1 represents a C 6 -C 10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C 1 -C 6 alkyl)amino group, a di-(C 1 -C 6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C 1 -C 6 alkyl group, and so on; L represents a sulfonyl group, an aminosulfonyl group, or a sulfonylamino group, and so on; R 2 represents a hydrogen atom, and so on; A represents a group defined by formula (II), (III), or (IV); R 3 represents a C 1 -C 6 alkyl group, and so on; and R 4 represents a C 1 -C 6 alkyl group, and so on.

专利号:US-8592448-B2
优先权日:2008-11-20
标题:Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
发明人：CHEN XIN; JIN MELZHONG; KLEINBERG ANDREW; LI AN-HU; MULVIHILL MARK J; STEINIG ARNO G; WANG JING
权利人:CHEN XIN; JIN MELZHONG; KLEINBERG ANDREW; LI AN-HU; MULVIHILL MARK J; STEINIG ARNO G; WANG JING; OSI PHARMACEUTICALS LLC
摘要:Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met.

专利号:US-7541367-B2
优先权日:2005-05-31
标 题 :3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
发明人：CHIU GEORGE; CONNOLLY PETER J; EMANUEL STUART; HUANG SHENLIN; LI SHENGJIAN; LIN RONGHUI; LU YANHUA; MIDDLETON STEVEN A
权利人:JANSSEN PHARMACEUTICA NV
摘要:The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I): n nand pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.